Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.50 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.47 |
| ▸ | NOS2 | P35228 | 6/20 | 0.45 |
| ▸ | NOS3 | P29474 | 5/20 | 0.45 |
| ▸ | NOS1 | P29475 | 5/20 | 0.45 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | ARG2 | P78540 | 4/20 | 0.40 |
| ▸ | ARG1 | P05089 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL27841789 | 1.00 | OTC (0.50) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL27562674 | 1.00 | OTC (0.50) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL27559277 | 1.00 | OTC (0.50) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL2899152 | 1.00 | OTC (0.50) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL29227441 | 0.98 | OTC (0.49) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL28208085 | 0.94 | OTC (0.46) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL26187286 | 0.94 | OTC (0.46) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL1668687 | 0.94 | OTC (0.46) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL2411547 | 0.93 | OTC (0.56) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL7928810 | 0.93 | OTC (0.56) | OTCDDAH1NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4314269-A1 | 3-METHYLCROTONIC ACID DECARBOXYLASE (MDC) VARIANTS | Global Bioenergies (FR) | 2024-02-07 | — | — | EP | claimed |
| WO-2024003376-A1 | DISPLACERS OF IGE-FCERI | Alk-Abelló A/S (DK) | 2024-01-04 | — | — | WO | claimed |
| WO-2022207684-A1 | 3-METHYLCROTONIC ACID DECARBOXYLASE (MDC) VARIANTS | GLOBAL BIOENERGIES (FR) | 2022-10-06 | — | — | WO | claimed |
| EP-3544992-A1 | G-PROTEIN-COUPLED RECEPTOR INTERNAL SENSORS | The Regents of The University of California (US) | 2019-10-02 | — | — | EP | claimed |
| WO-2018098262-A1 | G-PROTEIN-COUPLED RECEPTOR INTERNAL SENSORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-31 | — | — | WO | claimed |
| US-20150293023-A1 | SYSTEMS AND METHODS FOR MEASURING TRANSLATION OF TARGET PROTEINS IN CELLS | ANIMA CELL METROLOGY, INC. | 2015-10-15 | — | — | US | claimed |
| US-20140011977-A1 | CHIMERIC MOLECULES TO MODULATE GENE EXPRESSION | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2014-01-09 | — | — | US | claimed |
| US-20120183957-A1 | SYSTEMS AND METHODS FOR MEASURING TRANSLATION OF TARGET PROTEINS IN CELLS | ANIMA CELL METROLOGY, INC. (US) | 2012-07-19 | — | — | US | claimed |
| EP-1642910-B1 | Rationally designed antibodies | ALEXION PHARMA INC (US) | 2012-02-08 | — | — | EP | claimed |
| EP-1416972-B1 | CHIMERIC MOLECULES TO MODULATE GENE EXPRESSION | COLD SPRING HARBOR LAB (US) | 2012-02-08 | — | — | EP | claimed |
| EP-1589034-B1 | Rationally designed antibodies | ALEXION PHARMA INC (US) | 2008-11-19 | — | — | EP | claimed |
| EP-1642910-A1 | Rationally designed antibodies | ALEXION PHARMACEUTICALS, INC. (US) | 2006-04-05 | — | — | EP | claimed |
| EP-1370589-B1 | RATIONALLY DESIGNED ANTIBODIES | ALEXION PHARMA INC (US) | 2006-03-15 | — | — | EP | claimed |
| EP-1589034-A2 | Rationally designed antibodies | ALEXION PHARMACEUTICALS, INC. (US) | 2005-10-26 | — | — | EP | claimed |
| US-20050054836-A1 | Chimeric molecules to modulate gene expression | COLD SPRING HARBOR LABORATORY | 2005-03-10 | — | — | US | claimed |
| EP-1416972-A2 | CHIMERIC MOLECULES TO MODULATE GENE EXPRESSION | COLD SPRING HARBOR LABORATORY (US) | 2004-05-12 | — | — | EP | claimed |
| EP-1370589-A2 | RATIONALLY DESIGNED ANTIBODIES | ALEXION PHARMACEUTICALS, INC. (US) | 2003-12-17 | — | — | EP | claimed |
| US-20030049683-A1 | Immunoglobulin for use in human therapeutics and diagnostics | ALEXION PHARMACEUTICAL, INC. | 2003-03-13 | — | — | US | claimed |
| WO-2002046238-A2 | RATIONALLY DESIGNED ANTIBODIES | ALEXION PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | claimed |
| WO-2002038738-A2 | CHIMERIC MOLECULES TO MODULATE GENE EXPRESSION | COLD SPRING HARBOR LABORATORY (US) | 2002-05-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054836-A1 | Chimeric molecules to modulate gene expression | MYCBP, IGF2BP1, IGF2BP3 | OTC 4833/4885DDAH1 3359/4885NOS2 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.